Associated Papers
PPIA dictates NRF2 stability to promote lung cancer progression.
Lu W et al.
Nature Communications, 2024
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228.
Paik PK et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2023
Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer.
Bartolacci C et al.
Nature Communications, 2022
35882862 (PubMed )
Supplement: 41467_2022_31963_MOESM13_ESM.xlsx › Sheet1
Loss-of-function mutations in KEAP1 drive lung cancer progression via KEAP1/NRF2 pathway activation.
Gong M et al.
Cell Communication and Signaling : Ccs, 2020
Impacts of NRF2 activation in non-small-cell lung cancer cell lines on extracellular metabolites.
Saigusa D et al.
Cancer Science, 2020
31828882 (PubMed )
Supplement: CAS-111-667-s002.xlsx › Table_S2
Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer.
MacLeod AK et al.
British Journal of Cancer, 2016
27824809 (PubMed )
Supplement: bjc2016363x1.docx
Select a paper to view details